Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial.

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Journal of the American Medical Association (JAMA)

• Publication date

  2013-02-27

• Fields of study

  Medicine

• Identifiers
  DOI 10.1001/jama.2013.905PMID 23443441
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Serum aldosterone and its relationship to left ventricular structure and geometry in patients with preserved left ventricular ejection fraction.

  2012cited by this paper
• Effects of the long‐term administration of nebivolol on the clinical symptoms, exercise capacity, and left ventricular function of patients with diastolic dysfunction: results of the ELANDD study

  2012cited by this paper
• Aldosterone antagonists improve ejection fraction and functional capacity independently of functional class: a meta-analysis of randomised controlled trials

  2012cited by this paper
• The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial.

  2012cited by this paper
• What have we learned about patients with heart failure and preserved ejection fraction from DIG-PEF, CHARM-preserved, and I-PRESERVE?

  2012cited by this paper
• Impact of noncardiac comorbidities on morbidity and mortality in a predominantly male population with heart failure and preserved versus reduced ejection fraction.

  2012cited by this paper
• Results of the Randomized Aldosterone Antagonism in Heart Failure with Preserved Ejection Fraction trial (RAAM-PEF).

  2011cited by this paper
• Effects of treatment on exercise tolerance, cardiac function, and mortality in heart failure with preserved ejection fraction. A meta-analysis.

  2011cited by this paper
• Contribution of comorbidities to functional impairment is higher in heart failure with preserved than with reduced ejection fraction

  2011cited by this paper
• Rationale and design of the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial: a randomized, controlled study of spironolactone in patients with symptomatic heart failure and preserved ejection fraction.

  2011cited by this paper
• Eplerenone in patients with systolic heart failure and mild symptoms.

  2011cited by this paper
• [Summary of the article: Zannad F, McMurray JJV, Krum H et al.; for the EMPHASIS-HF Study Group. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med, 2011; 364: 11-21].

  2011cited by this paper
• Prognostic Value of Baseline Plasma Amino-Terminal Pro-Brain Natriuretic Peptide and Its Interactions With Irbesartan Treatment Effects in Patients With Heart Failure and Preserved Ejection Fraction: Findings From the I-PRESERVE Trial

  2011cited by this paper
• Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms

  2011cited by this paper
• Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment.

  2011cited by this paper
• A Randomized Double-Blind Trial of Enalapril in Older Patients With Heart Failure and Preserved Ejection Fraction: Effects on Exercise Tolerance and Arterial Distensibility

  2010cited by this paper
• Effect of spironolactone on left ventricular ejection fraction and volumes in patients with class I or II heart failure.

  2010cited by this paper
• Rationale and design of the ‘aldosterone receptor blockade in diastolic heart failure’ trial: a double‐blind, randomized, placebo‐controlled, parallel group study to determine the effects of spironolactone on exercise capacity and diastolic function in patients with symptomatic diastolic heart failu

  2010influential reference
• Testosterone Deficiency and Exercise Intolerance in Heart Failure: Treatment Implications

  2010cited by this paper
• Irbesartan in patients with heart failure and preserved ejection fraction.

  2008cited by this paper
• Clinimetrics Corner: The Minimal Clinically Important Change Score (MCID): A Necessary Pretense

  2008influential reference
• Death in Heart Failure: A Community Perspective

  2008cited by this paper
• Aldosterone receptor antagonism induces reverse remodeling when added to angiotensin receptor blockade in chronic heart failure.

  2007cited by this paper
• How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology.

  2007influential reference
• The incidence and implications of aldosterone breakthrough

  2007cited by this paper
• Effect of angiotensin receptor blockade and antihypertensive drugs on diastolic function in patients with hypertension and diastolic dysfunction: a randomised trial.

  2007cited by this paper
• FASTTRACK : The perindopril in elderly people with chronic heart failure (PEP-CHF) study

  2006cited by this paper
• Trends in prevalence and outcome of heart failure with preserved ejection fraction.

  2006cited by this paper
• Digoxin and reduction in mortality and hospitalization in heart failure: a comprehensive post hoc analysis of the DIG trial.

  2006cited by this paper
• Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study.

  2005cited by this paper
• Diastolic heart failure--abnormalities in active relaxation and passive stiffness of the left ventricle.

  2004cited by this paper
• Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study.

  2004cited by this paper
• Effect of Aldosterone Antagonism on Myocardial Dysfunction in Hypertensive Patients With Diastolic Heart Failure

  2004cited by this paper
• Eplerenone , a Selective Aldosterone Blocker , in Patients with Left Ventricular Dysfunction after Myocardial Infarction

  2003cited by this paper
• Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial.

  2003cited by this paper
• Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.

  2003cited by this paper
• EPLERENONE POST-ACUTE MYOCARDIAL INFARCTION HEART FAILURE EFFICACY AND SURVIVAL STUDY INVESTIGATORS. EPLERENONE, A SELECTIVE ALDOSTERONE BLOCKER, IN PATIENTS WITH LEFT VENTRICULAR DYSFUNCTION AFTER MYOCARDIAL INFARCTION

  2003cited by this paper
• Addition of spironolactone to angiotensin-converting enzyme inhibition in heart failure improves endothelial vasomotor dysfunction: role of vascular superoxide anion formation and endothelial nitric oxide synthase expression.

  2002cited by this paper
• Prevention of aortic and cardiac fibrosis by spironolactone in old normotensive rats.

  2001cited by this paper
• Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure.

  2001cited by this paper
• The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure

  2000cited by this paper
• Clinical Utility of Doppler Echocardiography and Tissue Doppler Imaging in the Estimation of Left Ventricular Filling Pressures: A Comparative Simultaneous Doppler-Catheterization Study

  2000cited by this paper
• Limitation of Excessive Extracellular Matrix Turnover May Contribute to Survival Benefit of Spironolactone Therapy in Patients With Congestive Heart Failure: Insights From the Randomized Aldactone Evaluation Study (RALES)

  2000cited by this paper
• Perindopril for elderly people with chronic heart failure: the PEP‐CHF study

  1999cited by this paper
• The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.

  1999cited by this paper
• Further evidence supporting an SEM-based criterion for identifying meaningful intra-individual changes in health-related quality of life.

  1999cited by this paper
• Validation and utility of a self-report version of PRIME-MD: the PHQ primary care study. Primary Care Evaluation of Mental Disorders. Patient Health Questionnaire.

  1999cited by this paper
• Validity of the Minnesota Living with Heart Failure questionnaire as a measure of therapeutic response to enalapril or placebo.

  1993cited by this paper
• The MOS 36-ltem Short-Form Health Survey (SF-36): I. Conceptual Framework and Item Selection

  1992cited by this paper
• The MOS 36-Item Short-Form Health Survey (SF-36)

  1992cited by this paper
• The Hospital Anxiety and Depression Scale.

  1987influential reference
• The Hospital Anxiety and Depression Scale

  1983cited by this paper
• Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.

  1975influential reference

• Spironolactone and Fibrosis in Heart Failure Risk: Machine Learning Analysis of HOMAGE Trial Plasma Proteomics.

  2026cites this paper
• The mineralocorticoid receptor: a new chapter for therapeutic regulation of diabetic cardiomyopathy.

  2026cites this paper
• The Japanese Society of Hypertension Guidelines for the management of elevated blood pressure and hypertension 2025 (JSH2025)

  2026cites this paper
• Understanding atrial failure: from diagnosis to clinical implications.

  2026cites this paper
• Early Initiation and Dose Optimization of Mineralocorticoid Receptor Antagonists in Heart Failure

  2026cites this paper
• Be mindful of additional risks when using guideline-directed medical therapy to treat heart failure with preserved ejection fraction in older adults

  2026cites this paper
• Insuficiencia cardíaca con fracción de eyección preservada: actualización en estrategias diagnósticas y terapéuticas. Documento de consenso de la SEMI

  2026cites this paper
• A multi-center, randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of Fuzheng Yangxin Granule in treating heart failure with preserved ejection fraction (Qi-Yin deficiency and blood stasis syndrome): study protocol

  2025cites this paper
• Systolic blood pressure lower than 130 mmHg in heart failure with preserved ejection fraction: a systematic review and meta-analysis of clinical outcomes

  2025cites this paper
• Anaemia in patients with heart failure and mildly reduced or preserved ejection fraction: A prespecified analysis of the FINEARTS‐HF trial

  2025cites this paper
• Cardiovascular-Kidney-Metabolic Health: Definition, Staging, Risk Assessment, and Therapeutic Considerations.

  2025cites this paper
• Beta-Blockers in Heart Failure With Preserved Ejection Fraction: A Declining Role in Contemporary Management.

  2025cites this paper
• “The Dynamic Duo”: The New Management of Drug Treatment for Heart Failure with Mildly Reduced or Preserved Ejection Fraction

  2025cites this paper
• The potential of spironolactone to mitigate the risk of nonalcoholic fatty liver disease in hypertensive populations: evidence from a cohort study

  2025cites this paper
• Finerenone in diabetic chronic kidney disease—Real‐world insights including patients with HFpEF or HFmrEF

  2025cites this paper
• Recent advances in mineralocorticoid receptor antagonists for heart failure with preserved ejection fraction: focus on finerenone in the era of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists

  2025cites this paper
• Heart Failure in 2025: Update With Perioperative Considerations.

  2025cites this paper
• Chronic Heart Failure and Coronary Artery Disease: Pharmacological Treatment and Cardiac Rehabilitation

  2025cites this paper
• When Kidney Function Declines But Therapy Still Works: The Case for Nonsteroidal MRA Therapy in Heart Failure.

  2025cites this paper
• Patient-Centered Outcomes in Heart Failure Pharmacotherapy

  2025cites this paper
• Aging and metabolism in HFpEF: Pathophysiology and therapeutic implications.

  2025cites this paper
• Unmasking Left Ventricular Diastolic Dysfunction: Pathophysiology, Diagnosis, and Treatment Strategies

  2025cites this paper
• Long-term hemodynamic responses and reverse remodeling after pharmacotherapy in HFpEF versus HFrEF: a systematic review and meta-analysis.

  2025cites this paper
• To MRAs treatment or not? evidence from a meta-analysis of randomized controlled trials of different MRAs on cardiovascular health in heart failure

  2025cites this paper
• Diagnosis and management of diastolic dysfunction in arterial hypertension.

  2025cites this paper
• Use of finerenone in patients with chronic kidney disease at high risk of heart failure.

  2025cites this paper
• Effects of geranylgeranylacetone on diastolic and microvascular function in patients with heart failure with a preserved ejection fraction: A phase 2, randomized, placebo‐controlled, crossover trial

  2025cites this paper
• A “Dupla Dinâmica”: O Novo Manejo no Tratamento Medicamentoso da Insuficiência Cardíaca com Fração de Ejeção Levemente Reduzida ou Preservada

  2025cites this paper
• Mineralocorticoid Receptor Antagonists in Heart Failure with Preserved Ejection Fraction: A Systematic Review and Meta-Analysis

  2025cites this paper
• Withdrawal of Spironolactone for Heart Failure With Improved Ejection Fraction: An Open-Label, Pilot, Randomized Controlled Trial (With-HF Trial)

  2025cites this paper
• Ventricular–Arterial Coupling in Heart Failure with Preserved Ejection Fraction: A Bibliometric Review and Clinical Implications

  2025cites this paper
• Pharmacologic Management of Heart Failure with Preserved Ejection Fraction (HFpEF) in Older Adults

  2025cites this paper
• Canadian Cardiovascular Society/Canadian Heart Failure Society 2025 Guideline Update for Pharmacologic Management of Heart Failure With Nonreduced Ejection Fraction (LVEF > 40%).

  2025cites this paper
• New Fuels for a Failing Engine: The Impact of Novel Heart Failure Drugs on Functional Capacity

  2025cites this paper
• Effects of Spironolactone on Diastolic Function in Patients with Heart Failure with Preserved Ejection Fraction

  2025cites this paper
• Efficacy and safety of finerenone in the treatment of primary aldosteronism: A prospective clinical study.

  2025cites this paper
• The Effect of Mineralocorticoid Receptor Antagonists on Heart Failure with Nonreduced Ejection Fraction: A Systematic Review and Meta-Analysis

  2025cites this paper
• Mineralocorticoid receptor antagonists in heart failure: a systematic review and meta-analysis

  2025cites this paper
• Glycometabolic cardiac dysfunction in HFpEF: lessons from multi-omics studies.

  2025cites this paper
• Cardiovascular-Kidney-Metabolic Effects: Steroidal and Nonsteroidal Mineralocorticoid Receptor Antagonists

  2025influential citation
• Diastolic Dysfunction and Renal Disease: Analysis, Mechanisms, and Different Perspectives

  2025cites this paper
• Underpinnings of heart failure with preserved ejection fraction in women - From prevention to improving function. A co-publication with the American Journal of Preventive Cardiology and the Journal of Cardiac Failure

  2025cites this paper
• Underpinnings of Heart Failure With Preserved Ejection Fraction in Women - From Prevention to Improving Function. A Co-publication With the American Journal of Preventive Cardiology and the Journal of Cardiac Failure.

  2025cites this paper
• The impact of combination of zofenopril and different diuretics on regression of myocardial reperfusion injury and oxidative status in spontaneously hypertensive rats

  2025cites this paper
• Cardiovascular Benefits of Spironolactone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction: Insights from a Win Ratio Analysis of the TOPCAT Trial

  2025influential citation
• Central Adiposity or Hypertension

  2025cites this paper
• Effects of finerenone on natriuretic peptide levels in heart failure with mildly reduced or preserved ejection fraction: The FINEARTS‐HF trial

  2025cites this paper
• Soluble urokinase plasminogen activator receptor and outcomes in HFpEF: A TOPCAT ancillary study

  2025cites this paper
• Renal Macro- and Microcirculatory Perturbations in Acute Kidney Injury and Chronic Kidney Disease Associated with Heart Failure and Cardiac Surgery.

  2025cites this paper
• Personalized app-based coaching for improving physical activity in heart failure with preserved ejection fraction patients compared with standard care: rationale and design of the MyoMobile Study

  2025cites this paper
• Obesity-Related Phenotype of Heart Failure With Preserved Ejection Fraction: A Comprehensive Review

  2025cites this paper
• Enhanced Decongestive Therapy in Patients With Acute Heart Failure: JACC Review Topic of the Week.

  2024cites this paper
• Proteomic profiles of left atrial volume and its influence on response to spironolactone: Findings from the HOMAGE trial and STANISLAS cohort

  2024cites this paper
• Aldosterone Effect on Cardiac Structure and Function

  2024cites this paper
• The Therapy and Management of Heart Failure with Preserved Ejection Fraction: New Insights on Treatment

  2024cites this paper
• Rest and exercise-stress estimated pulmonary capillary wedge pressure using real-time free-breathing cardiovascular magnetic resonance imaging

  2024cites this paper
• A “Periodic Table” approach to understand the pathophysiology of heart failure with preserved ejection fraction

  2024cites this paper
• Mineralocorticoid receptor antagonists for the prevention of atrial fibrillation in patients with and without heart failure: one more beneficial effect?

  2024cites this paper
• An altered plasma lipidome–phenome network characterizes heart failure with preserved ejection fraction

  2024cites this paper
• When to use either spironolactone, eplerenone or finerenone in the spectrum of cardiorenal diseases.

  2024cites this paper
• Drug Therapy for Acute and Chronic Heart Failure with Preserved Ejection Fraction with Hypertension: A State-of-the-Art Review

  2024cites this paper
• Assessment of diastolic dysfunction in controlled and uncontrolled hypertensive patients: A prospective observational study

  2024cites this paper
• Mineralocorticoid receptor antagonists and atrial fibrillation: a meta-analysis of clinical trials.

  2024cites this paper
• Heart failure with mildly reduced and preserved ejection fraction: A review of disease burden and remaining unmet medical needs within a new treatment landscape

  2024cites this paper
• Mineralocorticoid Receptor Antagonists in Heart Failure: An Update

  2024cites this paper
• The Spironolactone Initiation Registry Randomized Interventional Trial in Heart Failure with Preserved Ejection Fraction (SPIRRIT‐HFpEF): Rationale and design

  2024cites this paper
• Spironolactone Reduces the Risk of Death in Veterans With Heart Failure With Preserved Ejection Fraction

  2024cites this paper
• Sacubitril/valsartan reduces incident anaemia and iron therapy utilization in heart failure: The PARAGON‐HF trial

  2024cites this paper
• Mineralocorticoid Antagonism in Heart Failure: Established and Emerging Therapeutic Role.

  2024cites this paper
• Diastolische Herzinsuffizienz – Herzinsuffizienz mit erhaltener Ejektionsfraktion

  2024cites this paper
• Diastolic Dysfunction in Hypertension: A Comprehensive Review of Pathophysiology, Diagnosis, and Treatment.

  2024cites this paper
• Hypertension and Heart Failure: From Pathophysiology to Treatment

  2024cites this paper
• Effects of spironolactone on exercise blood pressure in patients at increased risk of developing heart failure: report from the HOMAGE trial

  2024cites this paper
• Evidence for Aldosterone Antagonism in Heart Failure

  2024cites this paper
• Finerenone in patients with heart failure with mildly reduced or preserved ejection fraction: Rationale and design of the FINEARTS‐HF trial

  2024cites this paper
• Mineralocorticoid receptor antagonists and heart failure with preserved ejection fraction: current understanding and future prospects

  2024cites this paper
• Heart rate reactivity, recovery, and endurance of the incremental shuttle walk test in patients prone to heart failure

  2024cites this paper
• Distinct Profiles and New Pharmacological Targets for Heart Failure with Preserved Ejection Fraction

  2024cites this paper
• Real-time cardiovascular magnetic resonance imaging for non-invasive characterisation of heart failure with preserved ejection fraction: final outcomes of the HFpEF stress trial

  2024cites this paper
• From urinary proteomic signature to individualised pharmacotherapy

  2024cites this paper
• Urinary proteomic signature of mineralocorticoid receptor antagonism by spironolactone: evidence from the HOMAGE trial

  2024cites this paper
• Epidemiology and Management of Patients With Kidney Disease and Heart Failure With Preserved Ejection Fraction.

  2024cites this paper
• Mineralocorticoid receptor antagonists for chronic heart failure: a meta-analysis focusing on the number needed to treat

  2023cites this paper
• Mixed-type Dyspnoea Diagnosed via Non-invasive and Invasive Cardiopulmonary Exercise Tests

  2023cites this paper
• Medical Management and Device-Based Therapies in Chronic Heart Failure

  2023cites this paper
• The prevalence of coronary microvascular dysfunction (CMD) in heart failure with preserved ejection fraction (HFpEF): a systematic review and meta-analysis

  2023cites this paper
• Rationale and design of the PACE HFpEF trial: Physiologic accelerated pacing as a holistic treatment of heart failure with preserved ejection fraction

  2023influential citation
• Interrelationship of Sarcopenia and Cardiovascular Diseases: A Review of Potential Mechanisms and Management

  2023cites this paper
• The inorganic NItrate and eXercise performance in Heart Failure (iNIX-HF) phase II clinical trial: Rationale and study design

  2023cites this paper
• Pharmacological Treatments in Heart Failure With Mildly Reduced and Preserved Ejection Fraction: Systematic Review and Network Meta-Analysis.

  2023cites this paper
• De Novo Lipogenesis-Related Monounsaturated Fatty Acids in the Blood Are Associated with Cardiovascular Risk Factors in HFpEF Patients

  2023influential citation
• Treatment response to spironolactone in patients with heart failure with preserved ejection fraction: a machine learning-based analysis of two randomized controlled trials

  2023cites this paper
• Serum aldosterone in right ventricular failure versus left ventricular failure before and after mineralocorticoid receptor antagonists: case-control clinical trial

  2023influential citation
• Repurposing the β3-Adrenergic Receptor Agonist Mirabegron in Patients With Structural Cardiac Disease

  2023cites this paper
• Mineralocorticoid receptor overactivation: targeting systemic impact with non-steroidal mineralocorticoid receptor antagonists

  2023cites this paper
• Pathophysiological Rationale and Clinical Evidence for Neurohormonal Modulation in Heart Failure with Preserved Ejection Fraction

  2023cites this paper
• Effect of bariatric surgery on cardio-psycho-metabolic outcomes in severe obesity: A randomized controlled trial.

  2023cites this paper
• Biomarkers to Guide Medical Therapy in Primary Aldosteronism.

  2023cites this paper
• Echocardiographic Evaluation of Spironolactone on Myocardial Remodeling in Atrial Fibrillation with Preserved Ejection Fraction: the INSPIRE-AF randomized controlled trial

  2023cites this paper
• Design and Baseline Characteristics of STEP-HFpEF Program Evaluating Semaglutide in Patients With Obesity HFpEF Phenotype.

  2023cites this paper